 "Natco gets USFDA acceptance for generic Copaxone")
Hyderabad-based Natco Pharma said that USFDA has accepted the abbreviated new drug application (ANDA) for generic Copaxone filed by its marketing partner in the US, Mylan.
Copaxone is indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS). It had US sales of approximately $ 411.5 million for the 12 months ending June 30, 2014, according to IMS Health.
Natco in a statement said that Mylan expects to be eligible for 180 days of marketing exclusivity in the US upon final FDA approval for the drug.
Copaxone is marketed by Teva Neuroscience Inc, which is a subsidiary of Teva, in the US.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app